13 results about "Tumour site" patented technology

This invention is related to the fields of medical biotechnology, nanobiotechnology, and nanomedicine. It involves a nanomedicine product that can release HOC1 (hypochlorous acid) at the tumor site in a controlled manner to treat lung cancer. HOC1 is a potent antimicrobial and antitumor agent that can target tumor tissues while minimizing damage to healthy tissues. The produced nanoparticles have a two-layer structure: the inner layer contains alginate, PFP (perfluoropentane), and Ca(OCl)2 to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.

A method for treating a tumor excise site defined by a center and edges is described. The method includes simultaneously exposing the tumor site to radiation containing fluid and pulsating thermally treated fluid, wherein the fluids are separate from each other and confined to a balloon. Also disclosed is a device for treating a tumor excise site defined by a center and edges. The device includes a reversibly deformable container positioned at the center, the container encapsulating thermally treated fluid; a first drainage conduit; and a second radio-isotope containing conduit contacting a second longitudinally extending surface of the first drainage conduit so as to be positioned between the first drainage conduit and the center.

The present application belongs to the technical field of nanometer material preparation, and relates to a kind of nanometer medicine, including medicine carrier and active ingredient, medicine carrier adopts amphiphilic polymer, and active ingredient includes photosensitizer Ce6 and analgesic drug LC. The preparation method of the nanometer medicine is also disclosed, comprising the following steps: weighing Ce6, analgesic drug LC and amphiphilic polymer, dissolving in solvent to obtain a mixed solution; the mixed solution is stirred uniformly, and dialyzed in ultrapure water; the solution obtained by dialysis is constant volume, and filtered to obtain nanometer medicine. The nanometer medicine particle size morphology is regular, the particle size is uniform, has good stability within 7 days, can have good enrichment effect at tumor site, and has good photodynamic therapy effect. Lidocaine and photosensitizer reach the lesion site at the same time through intravenous injection, not only reduce the operation steps, but also target the lesion site, reduce the anxiety of patients because they feel that anesthesia will affect intelligence.

The application provides a nano regulator and a preparation method and application thereof. Specifically, water regulation drugs and chemotherapy drugs are co-delivered through metal organic framework nanoparticles or metal polyphenol nanoparticles, the tumor-targeted enrichment and microenvironment-responsive release characteristics of the nano regulator are utilized to release the chemotherapy drugs at the tumor site after cryoablation. The nano regulator can be used for cryoablation sensitization and chemotherapy synergistic treatment, thereby effectively improving the tumor inhibition effect.

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

The application provides an embolism microsphere for regulating a tumor microenvironment and a preparation method and application thereof. The prepared embolism microsphere for regulating the tumor microenvironment is used for arterial tumor embolism, can embolize tumor blood vessels, block nutrition supply at a tumor site, and slowly and continuously release hydroxide in situ, neutralize lactic acid in the tumor microenvironment, regulate the weakly acidic tumor microenvironment, and improve the effect of chemotherapy, radiotherapy and immunotherapy.

The present application belongs to the technical field of biological macromolecule pharmaceutical chemistry and tumor targeting delivery system, and particularly relates to a polypeptide conjugate based on linaclotide and a preparation method and application thereof. The present application finds through experiments that linaclotide or its derivative has potential in colorectal cancer (CRC) targeting and deep penetration after proper modification, and therefore proposes a new use of the clinical drug linaclotide or its derivative in a tumor targeting drug delivery system, and constructs a polypeptide conjugate based on linaclotide or its derivative and a tumor targeting drug delivery system based thereon. In-vivo and in-vitro experiments prove that the polypeptide conjugate and the tumor targeting drug delivery system of the present application have precise targeting and deep penetration capabilities in colorectal cancer and metastatic tumors, can effectively enhance the accumulation of an antitumor drug at a tumor site, thereby enhancing the efficacy of the antitumor drug, and have a wide application prospect in the drug delivery system of colorectal cancer.

This invention belongs to the field of lipid nanoparticle preparation technology, specifically relating to a zwitterionic modified lipid nanoparticle, its preparation method, and its application. The zwitterionic modified lipid nanoparticle includes a lipid nanoparticle matrix and a lipid derivative modified on its surface, wherein the lipid derivative is a zwitterionic modified polypeptide; and the zwitterion is DSPE-PEG. The lipid nanoparticles of this invention possess a strong hydration layer, which can significantly reduce the production of APA in vivo, avoiding the ABC effect associated with repeated injections. In the presence of APA in vivo, it can reduce the impact of APA on the interaction between liposomes and immune cells, reduce the phagocytosis and clearance of lipid nanoparticles by the mononuclear phagocytic system, and prolong blood circulation time. Even with high levels of APA in vivo, it can still accumulate at the tumor site, further improving the therapeutic effect and providing an effective strategy to avoid the ABC effect.

The application belongs to the field of liposome drug delivery, and relates to a hypoxia-responsive prodrug liposome and a preparation and application thereof. The liposome contains a hypoxia-responsive prodrug and a photosensitizer, wherein the mass ratio between the hypoxia-responsive prodrug and the photosensitizer is 10:1-1:10; the hypoxia-responsive prodrug is a poorly soluble antitumor drug modified by a polyphenol. The hypoxia-responsive liposome prepared by the application has uniform particle size, high encapsulation efficiency and high drug loading capacity, good stability, significantly prolonged drug in-vivo circulation time and tumor site accumulation, and significantly improved antitumor effect. At the same time, the co-loaded liposome maintains fluorescence quenching in blood circulation, and specifically restores active oxygen capacity under the action of high glutathione in the tumor site, solving the problem of traditional photosensitizer phototoxicity.

The application discloses a kind of pemetrexed liposome and its preparation method and application, it is made of including 2mg / mL~20mg / mL pemetrexed or its pharmaceutically acceptable salt, 2.2mg / mL~12mg / mL cholesterols, 6.81mg / mL~108mg / mL neutral lipid, 12mg / mL~98mg / mL cationic lipid and 0.12mg / mL~2.12mg / mL PEG-lipid.The pemetrexed liposome of the application can significantly improve the enrichment of pemetrexed drug in tumor site, thereby enhancing drug treatment effect, reducing dosing dose, reducing the toxic side effects of drug on normal tissue.And it has good stability, no obvious change in storage process nature, particle size, zeta potential and encapsulation efficiency.

The present disclosure relates to the technical field of biological medicine, in particular to a polypeptide targeting PD-L1 and use thereof. The polypeptide provided by the present disclosure has high affinity and good stability. Based on the RDC of the polypeptide, the tumor primary lesion or metastatic lesion can be precisely targeted, and the polypeptide will not be retained in the tissues near the tumor and the tissues in non-tumor parts of the whole body, and the polypeptide can also avoid being rapidly degraded by proteases.

This invention addresses the lack of auxiliary devices for targeted radiation to the tumor site in existing intestinal implantation therapy. It provides a novel fixation mold for a rectal brazing radiotherapy applicator, comprising a connecting base and an implantation column. The implantation column is fixedly mounted on one side of the connecting base, which has connecting holes for connecting to external structures. The implantation column contains implantation holes parallel to its axis, distributed at equal angles around the axis of the column. These holes penetrate both the connecting base and the implantation column. By providing several equally angled implantation holes, it is easier to control the uneven distribution of implantation needles to correspond to eccentric rectal cancer tumors, thus achieving a more rational arrangement of the implantation needles.

This invention discloses a method for preparing and applying a self-cascaded reactive oxygen species amplifier (ROS) CHO@Cu / His-ZIF8. Belonging to the fields of nanomaterials and tumor therapy, the preparation steps are as follows: Histidine (His), 2-methylimidazole (2-MI), zinc nitrate, copper nitrate, and cholesterol oxidase are mixed uniformly in a specified ratio. After reacting for 24 hours, the mixture is washed, dialyzed, and dried to obtain the CHO@Cu / His-ZIF8 nanozyme. In this invention, the cholesterol oxidase activity, peroxidase activity (POD), and catalase activity of the CHO@Cu / His-ZIF8 nanozyme can form a cascade reaction, causing tumor cells to produce highly efficient reactive oxygen species and consume intratumoral cholesterol, thus inhibiting tumor cell growth and metastasis. Furthermore, the H2O2 produced by CHO-catalyzed cholesterol can be absorbed by Cu... 2+ The mediated Fenton-like reaction transforms into highly toxic hydroxyl radicals, amplifying oxidative damage to cancer cells. CHO@Cu / His-ZIF8 nanozymes exhibit tumor-specific killing effects on tumor cells, effectively accumulating at tumor sites while showing weak killing effects on normal sites, and possess good biocompatibility.